Ashwani Verma
Stock Analyst at UBS
(4.44)
# 1,172
Out of 4,649 analysts
228
Total ratings
61.1%
Success rate
12.6%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Rated: Hold | $28 | $20.37 | +37.46% | 10 | Aug 13, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $315 | $244.96 | +28.59% | 17 | Aug 11, 2026 | |
| RPRX Royalty Pharma | Maintained: Buy | $57 → $66 | $58.60 | +12.63% | 12 | Aug 11, 2026 | |
| MPLT MapLight Therapeutics | Downgraded: Hold | $52 → $13 | $11.75 | +10.64% | 3 | Aug 11, 2026 | |
| INSM Insmed | Maintained: Buy | $166 → $172 | $123.74 | +39.00% | 8 | Aug 7, 2026 | |
| VTRS Viatris | Maintained: Buy | $23 | $16.23 | +41.71% | 7 | Aug 7, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintained: Buy | $42 | $36.77 | +14.22% | 30 | Aug 7, 2026 | |
| AMRX Amneal Pharmaceuticals | Maintained: Buy | $23 → $25 | $18.15 | +37.74% | 4 | Aug 3, 2026 | |
| NBIX Neurocrine Biosciences | Maintained: Buy | $208 → $231 | $152.72 | +51.26% | 19 | Jul 31, 2026 | |
| INCY Incyte | Maintained: Hold | $113 | $120.16 | -5.96% | 13 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $55 → $85 | $84.70 | +0.35% | 2 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $669 | $507.56 | +31.81% | 1 | Jul 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $40 → $52 | $51.24 | +1.48% | 9 | Jul 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $69 → $115 | $74.13 | +55.13% | 13 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 | $14.64 | -24.86% | 6 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $95 → $72 | $114.47 | -37.10% | 2 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 → $48 | $49.06 | -2.16% | 7 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $251 → $259 | $213.67 | +21.21% | 12 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 → $6 | $4.06 | +47.97% | 3 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $645 → $705 | $499.73 | +41.08% | 19 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $40 | $28.24 | +41.64% | 10 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1,080 | $1,180.16 | -8.49% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $220 | $249.46 | -11.81% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 → $43 | $38.12 | +12.80% | 5 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $18 | $41.82 | n/a | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.05 → $1.1 | $1.20 | n/a | 7 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $119 → $130 | $209.83 | n/a | 4 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $3.47 | n/a | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $0.7961 | n/a | 1 | Oct 11, 2022 |
Legend Biotech
Aug 13, 2026
Rated: Hold
Price Target: $28
Current: $20.37
Upside: +37.46%
Jazz Pharmaceuticals
Aug 11, 2026
Reiterated: Buy
Price Target: $315
Current: $244.96
Upside: +28.59%
Royalty Pharma
Aug 11, 2026
Maintained: Buy
Price Target: $57 → $66
Current: $58.60
Upside: +12.63%
MapLight Therapeutics
Aug 11, 2026
Downgraded: Hold
Price Target: $52 → $13
Current: $11.75
Upside: +10.64%
Insmed
Aug 7, 2026
Maintained: Buy
Price Target: $166 → $172
Current: $123.74
Upside: +39.00%
Viatris
Aug 7, 2026
Maintained: Buy
Price Target: $23
Current: $16.23
Upside: +41.71%
Teva Pharmaceutical Industries
Aug 7, 2026
Maintained: Buy
Price Target: $42
Current: $36.77
Upside: +14.22%
Amneal Pharmaceuticals
Aug 3, 2026
Maintained: Buy
Price Target: $23 → $25
Current: $18.15
Upside: +37.74%
Neurocrine Biosciences
Jul 31, 2026
Maintained: Buy
Price Target: $208 → $231
Current: $152.72
Upside: +51.26%
Incyte
Jul 28, 2026
Maintained: Hold
Price Target: $113
Current: $120.16
Upside: -5.96%
Jul 28, 2026
Downgraded: Hold
Price Target: $55 → $85
Current: $84.70
Upside: +0.35%
Jul 21, 2026
Maintained: Buy
Price Target: $669
Current: $507.56
Upside: +31.81%
Jul 2, 2026
Rated: Hold
Price Target: $40 → $52
Current: $51.24
Upside: +1.48%
Jun 29, 2026
Upgraded: Buy
Price Target: $69 → $115
Current: $74.13
Upside: +55.13%
May 28, 2026
Reiterated: Hold
Price Target: $11
Current: $14.64
Upside: -24.86%
May 13, 2026
Upgraded: Buy
Price Target: $95 → $72
Current: $114.47
Upside: -37.10%
May 6, 2026
Maintained: Buy
Price Target: $42 → $48
Current: $49.06
Upside: -2.16%
Apr 10, 2026
Rated: Buy
Price Target: $251 → $259
Current: $213.67
Upside: +21.21%
Mar 24, 2026
Rated: Buy
Price Target: $10 → $6
Current: $4.06
Upside: +47.97%
Mar 5, 2026
Rated: Buy
Price Target: $645 → $705
Current: $499.73
Upside: +41.08%
Jan 5, 2026
Maintained: Buy
Price Target: $35 → $40
Current: $28.24
Upside: +41.64%
Nov 7, 2025
Maintained: Buy
Price Target: $1,080
Current: $1,180.16
Upside: -8.49%
Nov 7, 2025
Maintained: Hold
Price Target: $220
Current: $249.46
Upside: -11.81%
Oct 14, 2025
Maintained: Buy
Price Target: $50 → $43
Current: $38.12
Upside: +12.80%
Jul 29, 2025
Maintained: Hold
Price Target: $18
Current: $41.82
Upside: n/a
Jul 21, 2025
Maintained: Hold
Price Target: $1.05 → $1.1
Current: $1.20
Upside: n/a
Jul 14, 2025
Maintained: Hold
Price Target: $119 → $130
Current: $209.83
Upside: n/a
Jun 17, 2025
Maintained: Buy
Price Target: $5
Current: $3.47
Upside: n/a
Oct 11, 2022
Initiated Coverage: Buy
Price Target: $15
Current: $0.7961
Upside: n/a